Biotech M&A, Asset Valuation and Business Development
As an owner-managed Swiss advisory boutique, we provide Pharma and Biotech companies with the analytical precision and industry network required to navigate complex M&A transactions, business development initiatives and strategic partnerships.
Our Services
M&A and Business
Development
We advise Pharma and Biotech companies on strategic transformation projects, including:
-
Buy-side and sell-side M&A support, from deal sourcing to closing
-
Identification of target companies, licensing partners and pipeline assets
-
In- and out-licensing strategy and execution
-
Opportunity assessment and due diligence support
-
Deal structuring and negotiation guidance
Valuation and Financial Modeling
We deliver tailored valuation and financial analysis to support strategic decisions:
-
Risk-adjusted Net Present Value (rNPV) valuations of companies and assets
-
Sensitivity analysis to identify key value drivers
-
Scenario modeling to reflect different clinical development outcomes
-
Monte Carlo simulations for probabilistic assessments
Why Ocean21
We are a boutique advisory – and that is your advantage.
Independent &
execution-oriented
No standardized processes, no corporate templates. Just individually tailored strategies and full commitment.
Focus on Pharma & Biotech
We understand the scientific, regulatory, and commercial dynamics of our industry.
C-Level Experience
We speak the language of investors, founders, and industry partners, and bring them together.
Your Experts
Partner
With over 20 years of experience as an entrepreneur, in business development roles at Big Pharma, and in various commercial positions across listed companies and start-ups, Mischa brings a unique combination of strategic thinking and hands-on industry knowledge. He is passionate about the Pharmaceutical and Biotech industry and offers a strong understanding of its complex business dynamics. At Ocean21, Mischa advises clients on strategy development, partner identification, key transactions, and financial valuation.
.jpg)
Partner
As a goal-driven entrepreneur with more than 15 years of CFO, Controlling and Business Development experience, Ben brings strong analytical thinking, hands-on operational expertise, and proven M&A experience to Ocean21. Leveraging advanced technical skills and a deep understanding of financial dynamics, he adds structure and clarity to complex valuation scenarios and translates numbers into insights that clients can act on.
Partner
As a goal-driven entrepreneur with more than 15 years of CFO, Controlling and Business Development experience, Ben brings strong analytical thinking, hands-on operational expertise, and proven exit experience to Ocean21. Leveraging advanced technical skills and a deep understanding of financial dynamics, he adds structure and clarity to complex valuation scenarios and translates numbers into insights that clients can act on.
Partner
With over 35 years of experience in pharmaceutical business development, Ivan brings deep expertise in licensing, strategic partnering, and deal-making. He held senior roles at Novartis and later advised biotech and pharma companies across Europe. As a strong networker, Ivan is the Co-founder and past president of the Swiss Pharma Licensing Group and a past president of the European Pharma Licensing Council. He has also served on multiple Biotech boards, including as chairman, bringing strategic insight and hands-on governance experience to Ocean21 clients.
Partner
With over 20 years of experience as an entrepreneur, in business development roles at Big Pharma, and in various commercial positions across listed companies and start-ups, Mischa brings a unique combination of strategic thinking and hands-on industry knowledge. He is passionate about the Pharmaceutical and Biotech industry and offers a strong understanding of its complex business dynamics. At Ocean21, Mischa advises clients on strategy development, partner identification, key transactions, and financial valuation.
Partner
With over 35 years of experience in pharmaceutical business development, Ivan brings deep expertise in licensing, strategic partnering, and deal-making. He held senior roles at Novartis and later advised biotech and pharma companies across Europe. As a strong networker, Ivan is the Co-founder and past president of the Swiss Pharma Licensing Group and a past president of the European Pharma Licensing Council. He has also served on multiple Biotech boards, including as chairman, bringing strategic insight and hands-on governance experience to Ocean21 clients.
Our Network
We have access to an extensive network and can select highly qualified executives with strong track records in deal making to support project management and bring in specialized expertise from other advisors.This includes, for example, deep dives into pricing and market access, legal and financial due diligence, or contract drafting, always tailored to the specific needs of the project.
About Us
At Ocean21, our name defines our philosophy. Ocean symbolizes the depth, constant movement, and global interconnectivity of the Biotech and Pharma industries. We navigate these complexities daily, turning industry uncertainty into a competitive advantage.
21 represents the 21st century—an era of rapid medical innovation, technological progress, and global challenges. Together, Ocean21 is our commitment to guiding Life Science decision-makers through complex M&A transactions and global growth strategies with entrepreneurial thinking and analytical precision.
From complex M&A and licensing transactions to biotech company valuations (rNPV) and strategic partner identification, we provide the support you need.
With deep Life Science expertise, entrepreneurial insight, and analytical precision, we deliver a clear, execution-focused approach to every engagement. Whether you are seeking a sell-side advisor or a strategic growth partner, our team ensures your transaction's success in the 21st-century market.
Ocean21 GmbH
Nidelbadstrasse 65, 8038 Zürich, Switzerland | contact@ocean21.ch
CHE-134.891.823
Designed by Muriel Imfeld